Evaluation of thyroid function monitoring in people treated with lithium: Advice based on real‐world data

Introduction Blood test monitoring is essential for the management of lithium treatment and National Institute for Health and Care Excellence guidance recommends 6‐monthly serum testing of thyroid function. We examined conformity to these guidelines and the impact of monitoring outside these interva...

Full description

Saved in:
Bibliographic Details
Published inBipolar disorders Vol. 25; no. 5; pp. 402 - 409
Main Authors Duce, Helen L., Duff, Christopher J., Zaidi, Syed, Parfitt, Ceri, Heald, Adrian H., Fryer, Anthony A.
Format Journal Article
LanguageEnglish
Published Denmark Wiley Subscription Services, Inc 01.08.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Introduction Blood test monitoring is essential for the management of lithium treatment and National Institute for Health and Care Excellence guidance recommends 6‐monthly serum testing of thyroid function. We examined conformity to these guidelines and the impact of monitoring outside these intervals. Methods We extracted serum lithium and thyroid hormone results at one centre between January 2009 and December 2020. We identified 266 patients who started lithium during this period with no history of thyroid abnormality within the previous 2 years and were at risk of developing thyroid abnormalities. We examined the interval between tests, time between onset of lithium testing and first thyroid‐stimulating hormone (TSH) outside the laboratory reference range and assessed impact of testing outside recommended 6‐monthly intervals. Results The most common testing frequency was 3 months (±1 month), accounting for 17.3% of test intervals. Kaplan‐Meier analysis showed that most thyroid dysfunction manifests within 3 years (proportion with abnormal TSH at 3 years = 91.4%, 19.9% of total patients). In the first 3 months after commencing lithium therapy, eight patients developed subclinical hypothyroidism and had clinical follow‐up data available. Of these, half spontaneously normalized without clinical intervention. In the remaining patients, thyroxine replacement was only initiated after multiple occasions of subclinical hypothyroidism (median = 2 years after initiating lithium, range: 6 months to 3 years). Conclusion The peak interval at 3 months suggests that thyroid function is frequently checked at the same time as serum lithium, indicating too frequent testing. Our data support the recommended 6‐monthly testing interval and highlight poor adherence to it.
AbstractList INTRODUCTIONBlood test monitoring is essential for the management of lithium treatment and National Institute for Health and Care Excellence guidance recommends 6-monthly serum testing of thyroid function. We examined conformity to these guidelines and the impact of monitoring outside these intervals. METHODSWe extracted serum lithium and thyroid hormone results at one centre between January 2009 and December 2020. We identified 266 patients who started lithium during this period with no history of thyroid abnormality within the previous 2 years and were at risk of developing thyroid abnormalities. We examined the interval between tests, time between onset of lithium testing and first thyroid-stimulating hormone (TSH) outside the laboratory reference range and assessed impact of testing outside recommended 6-monthly intervals. RESULTSThe most common testing frequency was 3 months (±1 month), accounting for 17.3% of test intervals. Kaplan-Meier analysis showed that most thyroid dysfunction manifests within 3 years (proportion with abnormal TSH at 3 years = 91.4%, 19.9% of total patients). In the first 3 months after commencing lithium therapy, eight patients developed subclinical hypothyroidism and had clinical follow-up data available. Of these, half spontaneously normalized without clinical intervention. In the remaining patients, thyroxine replacement was only initiated after multiple occasions of subclinical hypothyroidism (median = 2 years after initiating lithium, range: 6 months to 3 years). CONCLUSIONThe peak interval at 3 months suggests that thyroid function is frequently checked at the same time as serum lithium, indicating too frequent testing. Our data support the recommended 6-monthly testing interval and highlight poor adherence to it.
Abstract Introduction Blood test monitoring is essential for the management of lithium treatment and National Institute for Health and Care Excellence guidance recommends 6‐monthly serum testing of thyroid function. We examined conformity to these guidelines and the impact of monitoring outside these intervals. Methods We extracted serum lithium and thyroid hormone results at one centre between January 2009 and December 2020. We identified 266 patients who started lithium during this period with no history of thyroid abnormality within the previous 2 years and were at risk of developing thyroid abnormalities. We examined the interval between tests, time between onset of lithium testing and first thyroid‐stimulating hormone (TSH) outside the laboratory reference range and assessed impact of testing outside recommended 6‐monthly intervals. Results The most common testing frequency was 3 months (±1 month), accounting for 17.3% of test intervals. Kaplan‐Meier analysis showed that most thyroid dysfunction manifests within 3 years (proportion with abnormal TSH at 3 years = 91.4%, 19.9% of total patients). In the first 3 months after commencing lithium therapy, eight patients developed subclinical hypothyroidism and had clinical follow‐up data available. Of these, half spontaneously normalized without clinical intervention. In the remaining patients, thyroxine replacement was only initiated after multiple occasions of subclinical hypothyroidism (median = 2 years after initiating lithium, range: 6 months to 3 years). Conclusion The peak interval at 3 months suggests that thyroid function is frequently checked at the same time as serum lithium, indicating too frequent testing. Our data support the recommended 6‐monthly testing interval and highlight poor adherence to it.
Introduction Blood test monitoring is essential for the management of lithium treatment and National Institute for Health and Care Excellence guidance recommends 6‐monthly serum testing of thyroid function. We examined conformity to these guidelines and the impact of monitoring outside these intervals. Methods We extracted serum lithium and thyroid hormone results at one centre between January 2009 and December 2020. We identified 266 patients who started lithium during this period with no history of thyroid abnormality within the previous 2 years and were at risk of developing thyroid abnormalities. We examined the interval between tests, time between onset of lithium testing and first thyroid‐stimulating hormone (TSH) outside the laboratory reference range and assessed impact of testing outside recommended 6‐monthly intervals. Results The most common testing frequency was 3 months (±1 month), accounting for 17.3% of test intervals. Kaplan‐Meier analysis showed that most thyroid dysfunction manifests within 3 years (proportion with abnormal TSH at 3 years = 91.4%, 19.9% of total patients). In the first 3 months after commencing lithium therapy, eight patients developed subclinical hypothyroidism and had clinical follow‐up data available. Of these, half spontaneously normalized without clinical intervention. In the remaining patients, thyroxine replacement was only initiated after multiple occasions of subclinical hypothyroidism (median = 2 years after initiating lithium, range: 6 months to 3 years). Conclusion The peak interval at 3 months suggests that thyroid function is frequently checked at the same time as serum lithium, indicating too frequent testing. Our data support the recommended 6‐monthly testing interval and highlight poor adherence to it.
Blood test monitoring is essential for the management of lithium treatment and National Institute for Health and Care Excellence guidance recommends 6-monthly serum testing of thyroid function. We examined conformity to these guidelines and the impact of monitoring outside these intervals. We extracted serum lithium and thyroid hormone results at one centre between January 2009 and December 2020. We identified 266 patients who started lithium during this period with no history of thyroid abnormality within the previous 2 years and were at risk of developing thyroid abnormalities. We examined the interval between tests, time between onset of lithium testing and first thyroid-stimulating hormone (TSH) outside the laboratory reference range and assessed impact of testing outside recommended 6-monthly intervals. The most common testing frequency was 3 months (±1 month), accounting for 17.3% of test intervals. Kaplan-Meier analysis showed that most thyroid dysfunction manifests within 3 years (proportion with abnormal TSH at 3 years = 91.4%, 19.9% of total patients). In the first 3 months after commencing lithium therapy, eight patients developed subclinical hypothyroidism and had clinical follow-up data available. Of these, half spontaneously normalized without clinical intervention. In the remaining patients, thyroxine replacement was only initiated after multiple occasions of subclinical hypothyroidism (median = 2 years after initiating lithium, range: 6 months to 3 years). The peak interval at 3 months suggests that thyroid function is frequently checked at the same time as serum lithium, indicating too frequent testing. Our data support the recommended 6-monthly testing interval and highlight poor adherence to it.
Author Parfitt, Ceri
Fryer, Anthony A.
Duff, Christopher J.
Heald, Adrian H.
Duce, Helen L.
Zaidi, Syed
Author_xml – sequence: 1
  givenname: Helen L.
  orcidid: 0000-0002-5256-169X
  surname: Duce
  fullname: Duce, Helen L.
  organization: University Hospitals of North Midlands NHS Trust
– sequence: 2
  givenname: Christopher J.
  surname: Duff
  fullname: Duff, Christopher J.
  organization: Keele University
– sequence: 3
  givenname: Syed
  surname: Zaidi
  fullname: Zaidi, Syed
  organization: University Hospitals of North Midlands NHS Trust
– sequence: 4
  givenname: Ceri
  surname: Parfitt
  fullname: Parfitt, Ceri
  organization: University Hospitals of North Midlands NHS Trust
– sequence: 5
  givenname: Adrian H.
  surname: Heald
  fullname: Heald, Adrian H.
  organization: The University of Manchester
– sequence: 6
  givenname: Anthony A.
  surname: Fryer
  fullname: Fryer, Anthony A.
  email: a.a.fryer@keele.ac.uk
  organization: Keele University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36645255$$D View this record in MEDLINE/PubMed
BookMark eNp1kc9OHSEUxkmjqX_aRV_AkHTTLq4CM3ChO7W2mpi4adfkDDAVZeAKM97cXR-hz9gnEe9VFyYeksMJ_PhyON8e2oopOoQ-UXJIaxx11h_Shin5Du3SRqkZF1RurWtZ63a-g_ZKuSGECkb4e7TTCNFyxvkuuj27hzDB6FPEqcfj9Sonb3E_RbM-G1L0Y8o-_sE-4oVLi-DwmB2MzuKlH69xqMlPwzd8bO-9cbiDUq_q0wqF_3__LVMOFlsY4QPa7iEU9_Fp30e_f5z9Oj2fXV79vDg9vpyZRko5g14p1XJqhKBOMNWDMKRzBqwiLRhRP2XkvGWyaxgwUZdSnWw7MLYDNYdmH33Z6C5yuptcGfXgi3EhQHRpKprNhSCibQiv6OdX6E2acqzdaSZ5nRevLVXq64YyOZWSXa8X2Q-QV5oS_eiArg7otQOVPXhSnLrB2RfyeeQVONoASx_c6m0lffL9YiP5AAdRkrE
CitedBy_id crossref_primary_10_1080_14737175_2023_2181076
crossref_primary_10_2174_1574885518666230710122712
crossref_primary_10_1016_j_ando_2023_03_004
crossref_primary_10_1111_bdi_13377
Cites_doi 10.1111/bdi.12681
10.1111/ijcp.14447
10.1111/bdi.12805
10.1186/s40345-016-0068-y
10.1016/S0140-6736(14)61842-0
10.1177/0269881118760663
10.1177/0269881119882858
10.1192/bjo.2021.1027
10.1016/j.jad.2015.04.055
10.1186/s12888-020-03023-y
10.1055/s-0043-103018
10.1007/BF03346311
10.1373/clinchem.2011.176487
10.1186/1756-6614-6-3
10.1111/ijcp.13277
ContentType Journal Article
Copyright 2023 The Authors. published by John Wiley & Sons Ltd.
2023 The Authors. Bipolar Disorders published by John Wiley & Sons Ltd.
2023. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2023 The Authors. published by John Wiley & Sons Ltd.
– notice: 2023 The Authors. Bipolar Disorders published by John Wiley & Sons Ltd.
– notice: 2023. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TK
7X8
DOI 10.1111/bdi.13298
DatabaseName Wiley-Blackwell Open Access Collection
Wiley-Blackwell Backfiles (Open access)
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
Neurosciences Abstracts

MEDLINE
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley-Blackwell Open Access Collection
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1399-5618
EndPage 409
ExternalDocumentID 10_1111_bdi_13298
36645255
BDI13298
Genre article
Journal Article
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1OC
23N
24P
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIVO
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
YFH
ZZTAW
~IA
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TK
7X8
ID FETCH-LOGICAL-c3888-af999451c661e629fa6c0becad904ac6398c87428b32a2626299b84bacdba97a3
IEDL.DBID 24P
ISSN 1398-5647
IngestDate Fri Aug 16 02:10:17 EDT 2024
Fri Sep 13 08:33:38 EDT 2024
Fri Aug 23 01:32:23 EDT 2024
Wed Oct 09 10:29:29 EDT 2024
Sat Aug 24 00:57:54 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords lithium
interval
thyroid
monitoring
Language English
License Attribution
2023 The Authors. Bipolar Disorders published by John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3888-af999451c661e629fa6c0becad904ac6398c87428b32a2626299b84bacdba97a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5256-169X
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbdi.13298
PMID 36645255
PQID 2850165388
PQPubID 2045186
PageCount 8
ParticipantIDs proquest_miscellaneous_2766064305
proquest_journals_2850165388
crossref_primary_10_1111_bdi_13298
pubmed_primary_36645255
wiley_primary_10_1111_bdi_13298_BDI13298
PublicationCentury 2000
PublicationDate August 2023
2023-08-00
20230801
PublicationDateYYYYMMDD 2023-08-01
PublicationDate_xml – month: 08
  year: 2023
  text: August 2023
PublicationDecade 2020
PublicationPlace Denmark
PublicationPlace_xml – name: Denmark
– name: Hoboken
PublicationTitle Bipolar disorders
PublicationTitleAlternate Bipolar Disord
PublicationYear 2023
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2016; 4
2021; 8
2015; 183
2021; 21
2021; 75
2019; 73
2021
2019; 21
2020; 71
2015; 386
2019
2020; 34
2014
2007; 30
2012; 58
2018; 32
2018; 20
2013; 6
2017; 125
e_1_2_8_17_1
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_14_1
e_1_2_8_15_1
e_1_2_8_16_1
e_1_2_8_3_1
e_1_2_8_2_1
e_1_2_8_5_1
Czarnywojtek A (e_1_2_8_10_1) 2020; 71
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_11_1
e_1_2_8_12_1
Holland D (e_1_2_8_18_1) 2021
References_xml – volume: 183
  start-page: 159
  year: 2015
  end-page: 165
  article-title: Lithium is associated with decrease in all‐cause and suicide mortality in high‐risk bipolar patients: a nationwide registry‐based prospective cohort study
  publication-title: J Affect Disord
– volume: 386
  start-page: 461
  issue: 9992
  year: 2015
  end-page: 468
  article-title: Long‐term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data
  publication-title: Lancet
– volume: 73
  issue: 4
  year: 2019
  article-title: More frequent lithium testing in UK primary care associates with a lower hospital admission rate for bipolar disorder‐what this can tell us about GP practice engagement with this group
  publication-title: Int J Clin Pract
– volume: 8
  issue: 1
  year: 2021
  article-title: Can we check serum lithium levels less often without compromising patient safety?
  publication-title: BJPsych Open
– volume: 75
  issue: 9
  year: 2021
  article-title: Inadequate postpartum screening for type 2 diabetes in women with previous gestation diabetes mellitus: a retrospective audit of practice over 17 years
  publication-title: Int J Clin Pract
– volume: 125
  start-page: 625
  issue: 9
  year: 2017
  end-page: 633
  article-title: Monitoring thyroid function in patients on levothyroxine. Assessment of conformity to National Guidance and variability in practice
  publication-title: Exp Clin Endocrinol Diabetes
– volume: 21
  start-page: 394
  year: 2019
  end-page: 409
  article-title: What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI task force on treatment with lithium
  publication-title: Bipolar Disord
– volume: 21
  start-page: 32
  issue: 1
  year: 2021
  article-title: Serum lithium test requesting across three UK regions: an evaluation of adherence to monitoring guidelines
  publication-title: BMC Psychiatry
– volume: 20
  start-page: 708
  year: 2018
  end-page: 720
  article-title: Evaluation of clarity of presentation and applicability of monitoring instructions for patients using lithium in clinical practice guidelines for treatment of bipolar disorder
  publication-title: Bipolar Disord
– volume: 6
  start-page: 3
  year: 2013
  article-title: Spectrum of lithium induced thyroid abnormalities: a current perspective
  publication-title: Thyroid Res
– volume: 32
  start-page: 408
  year: 2018
  end-page: 415
  article-title: Is lithium monitoring NICE? Lithium monitoring in a UK secondary care setting
  publication-title: J Psychopharmacol
– volume: 4
  start-page: 27
  year: 2016
  article-title: Lithium side effects and toxicity: prevalence and management strategies
  publication-title: Int J Bipolar Disord
– volume: 30
  start-page: 363
  issue: 5
  year: 2007
  end-page: 366
  article-title: Fifteen‐year follow‐up of thyroid function in lithium patients
  publication-title: J Endocrinol Invest
– volume: 71
  start-page: 191
  issue: 2
  year: 2020
  end-page: 199
  article-title: Effect of lithium carbonate on the function of the thyroid gland: mechanism of action and clinical implications
  publication-title: J Physiol Pharmacol
– volume: 34
  start-page: 293
  issue: 3
  year: 2020
  end-page: 303
  article-title: Lithium‐associated hypothyroidism and potential for reversibility after lithium discontinuation: findings from the LiSIE retrospective cohort study
  publication-title: J Psychopharmacol
– year: 2019
– year: 2014
– volume: 58
  start-page: 906
  issue: 5
  year: 2012
  end-page: 915
  article-title: Inappropriate requesting of glycated hemoglobin (Hb A1c) is widespread: assessment of prevalence, impact of national guidance, and practice‐to‐practice variability
  publication-title: Clin Chem
– year: 2021
  article-title: Assessment of the effect of the COVID‐19 pandemic on UK HbA1c testing: implications for diabetes management and diagnosis
  publication-title: J Clin Pathol
– ident: e_1_2_8_3_1
  doi: 10.1111/bdi.12681
– ident: e_1_2_8_2_1
– ident: e_1_2_8_16_1
  doi: 10.1111/ijcp.14447
– ident: e_1_2_8_5_1
  doi: 10.1111/bdi.12805
– ident: e_1_2_8_7_1
  doi: 10.1186/s40345-016-0068-y
– ident: e_1_2_8_9_1
  doi: 10.1016/S0140-6736(14)61842-0
– year: 2021
  ident: e_1_2_8_18_1
  article-title: Assessment of the effect of the COVID‐19 pandemic on UK HbA1c testing: implications for diabetes management and diagnosis
  publication-title: J Clin Pathol
  contributor:
    fullname: Holland D
– ident: e_1_2_8_20_1
– volume: 71
  start-page: 191
  issue: 2
  year: 2020
  ident: e_1_2_8_10_1
  article-title: Effect of lithium carbonate on the function of the thyroid gland: mechanism of action and clinical implications
  publication-title: J Physiol Pharmacol
  contributor:
    fullname: Czarnywojtek A
– ident: e_1_2_8_4_1
  doi: 10.1177/0269881118760663
– ident: e_1_2_8_11_1
  doi: 10.1177/0269881119882858
– ident: e_1_2_8_14_1
  doi: 10.1192/bjo.2021.1027
– ident: e_1_2_8_6_1
  doi: 10.1016/j.jad.2015.04.055
– ident: e_1_2_8_12_1
  doi: 10.1186/s12888-020-03023-y
– ident: e_1_2_8_17_1
  doi: 10.1055/s-0043-103018
– ident: e_1_2_8_19_1
  doi: 10.1007/BF03346311
– ident: e_1_2_8_15_1
  doi: 10.1373/clinchem.2011.176487
– ident: e_1_2_8_8_1
  doi: 10.1186/1756-6614-6-3
– ident: e_1_2_8_13_1
  doi: 10.1111/ijcp.13277
SSID ssj0016205
Score 2.471006
Snippet Introduction Blood test monitoring is essential for the management of lithium treatment and National Institute for Health and Care Excellence guidance...
Blood test monitoring is essential for the management of lithium treatment and National Institute for Health and Care Excellence guidance recommends 6-monthly...
Abstract Introduction Blood test monitoring is essential for the management of lithium treatment and National Institute for Health and Care Excellence guidance...
IntroductionBlood test monitoring is essential for the management of lithium treatment and National Institute for Health and Care Excellence guidance...
INTRODUCTIONBlood test monitoring is essential for the management of lithium treatment and National Institute for Health and Care Excellence guidance...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 402
SubjectTerms Bipolar Disorder - chemically induced
Bipolar Disorder - drug therapy
Humans
Hypothyroidism
Hypothyroidism - drug therapy
interval
Lithium
Lithium - therapeutic use
monitoring
Patients
thyroid
Thyroid Diseases
Thyroid gland
Thyroid-stimulating hormone
Thyrotropin
Thyroxine
Title Evaluation of thyroid function monitoring in people treated with lithium: Advice based on real‐world data
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbdi.13298
https://www.ncbi.nlm.nih.gov/pubmed/36645255
https://www.proquest.com/docview/2850165388/abstract/
https://search.proquest.com/docview/2766064305
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dS8MwED_mBPFF_HZ-EcUHXyrrR9JUn9RtTGEi4mBvJU1aHLpOpnv3T_Bv9C_xLu2KQwRfSmkupNzlcr_LXS4AJxIFK3iYOj4u_uig8MiJQk84masC7SqFFowcxd6d6PaD2wEf1OBidhamqA9RbbiRZtj1mhRcJW8_lDwxwzO6JV0uwCLCGklT2gvuqxCC8Gz-IiIc6XARhGVZIUrjqbrOG6NfCHMesFqL01mFlRIqsstCtmtQS_N1WOqVwfANeG5XlbrZOGPI8cl4aBhZKvttZNWV9u3YMGdFqjizieWpYbT_yhCCPw2no3N2aWjBYGTSDMOuSPTy9fFpy6kySiLdhH6n_Xjddcq7Exzto1PrqAyRX8BdjSJIhRdlSugmykuZqBkojbhEaolusUx8T3no1aBZSmSQKG0SFYXK34J6Ps7THWC-dl0fVV0nmgi4kipLXR5mmZEmUkEDjmdMjF-LEhnxzLVATseW0w3Yn7E3LrXkLfYkp9NU-MMNOKqacX5T0ELl6XiKNKEQBJuavAHbhViqUXB-UVgWW06tnP4ePr5q3diX3f-T7sEy3S1fZPvtQ_19Mk0PEIG8J4d2puGz9eB9Azzl1xc
link.rule.ids 315,786,790,1382,11589,27957,27958,46087,46329,46511,46753
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT8MwDLZ4SMAF8WYwICAOXIrWR9IUceGpAdvEYZO4VWnSignWIdju_AR-I78EO-0qEELiVrWOUtlx_PkRB-BQomAFD1PHx80fHRQeOVHoCSdzVaBdpdCCkaPY7ohmL7h94A9TcDo5C1P0h6gCbqQZdr8mBaeA9DctT0z_mK5Jl9MwSzd6k1p6wX2VQxCeLWBEiCMdLoKw7CtEdTzV0J_W6BfE_IlYrcm5XoLFEiuys0K4yzCV5isw1y6z4avwdFW16mbDjCHLX4d9w8hU2XcDq68UuGP9nBW14sxWlqeGUQCWIQZ_7I8HJ-zM0I7ByKYZhkOR6Pnz_cP2U2VURboGveur7kXTKS9PcLSPXq2jMoR-AXc1yiAVXpQpoRsoMGWiRqA0AhOpJfrFMvE95aFbg3YpkUGitElUFCp_HWbyYZ5uAvO16_qo6zrRRMCVVFnq8jDLjDSRCmpwMGFi_FL0yIgnvgVyOracrkF9wt64VJO32JOcjlPhD9dgv_qMC5yyFipPh2OkCYUg3NTgNdgoxFLNgguM8rL45cjK6e_p4_PLG_uw9X_SPZhvdtutuHXTuduGBbpovij9q8PM6HWc7iAcGSW7dtV9AbNG2Y8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT8MwDLZ4SBMXxJvxDIgDl6K1TdIUTrwmXpt2AIlblSatmGAdAnbnJ_Ab-SXYaVeBEBK3KnGUyo7jz7HjAOwpFKwUUeaFuPmjgyJiL44C6eW-5sbXGi0YOYqdrry441f34n4CjsZ3Ycr6EPWBG2mG269JwZ9t_k3JU9s_oFfS1SRMc9lS5HkFvFeHEGTg8hcR4ShPSB5VZYUojace-tMY_UKYPwGrszjtOZitoCI7LmU7DxNZsQCNThUMX4TH87pSNxvmDDn-MuxbRpbKtQ2cutK5HesXrEwVZy6xPLOMzl8ZQvCH_mhwyI4tbRiMTJplOBSJnj7fP1w5VUZJpEtw1z6_Pb3wqrcTPBOiU-vpHJEfF75BEWQyiHMtTQvlpW3c4togLlFGoVus0jDQAXo1aJZSxVNtbKrjSIfLMFUMi2wVWGh8P0RVN6khAqGVzjNfRHlulY01b8LumInJc1kiIxm7FsjpxHG6CRtj9iaVlrwmgRJ0mwp_uAk7dTeubwpa6CIbjpAmkpJgU0s0YaUUSz0Lri8Ky2LPvpPT39MnJ2eX7mPt_6Tb0OidtZOby-71OszQM_Nl4t8GTL29jLJNBCNv6ZZbdF-QwdjB
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+thyroid+function+monitoring+in+people+treated+with+lithium%3A+Advice+based+on+real%E2%80%90world+data&rft.jtitle=Bipolar+disorders&rft.au=Duce%2C+Helen+L&rft.au=Duff%2C+Christopher+J&rft.au=Zaidi%2C+Syed&rft.au=Parfitt%2C+Ceri&rft.date=2023-08-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1398-5647&rft.eissn=1399-5618&rft.volume=25&rft.issue=5&rft.spage=402&rft.epage=409&rft_id=info:doi/10.1111%2Fbdi.13298&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1398-5647&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1398-5647&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1398-5647&client=summon